OPDP sends Warning Letter to Acorda

Share this article:

OPDP hit Acorda Therapeutics with a warning letter dated July 25 for an Ampyra print ad. The agency's ad lookout said the company's print ad in a February issue of the Des Moines Sunday Register failed to include risk information, rendering it false or misleading.

The ad was an invitation to a multiple sclerosis presentation, and featured the company logo and drug name as well as some drug benefit statements. It also included the statement, “This presentation is not medical advice or an attempt to provide medical advice” and says readers should talk to a healthcare provider to discuss the treatment.

OPDP says the provider language doesn't cut it, because “this does not mitigate the misleading omission of risk information from the print ad.”

The July note was not limited to the February transgression, and doubled as an expression of frustration, saying Acorda's misleading ad is “particularly troubling considering OPDP expressed concerns regarding violative promotional activities as recently as June 21, 2012.” A 2012 Acorda Amypra video triggered an untitled letter that said the drug's efficacy was overstated and risk information minimized.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...